Arcturus Therapeutics (ARCT) Gets a Hold Rating from Raymond James

In a report released yesterday, Steven Seedhouse from Raymond James maintained a Hold rating on Arcturus Therapeutics (ARCTResearch Report). The company’s shares closed last Monday at $54.64.

According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of 15.4% and a 57.2% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Alexion Pharmaceuticals, and Apellis Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arcturus Therapeutics with a $81.70 average price target, a 52.0% upside from current levels. In a report issued on February 23, H.C. Wainwright also downgraded the stock to Hold with a $50.00 price target.

See today’s analyst top recommended stocks >>

Based on Arcturus Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.33 million and GAAP net loss of $21 million. In comparison, last year the company earned revenue of $3.32 million and had a GAAP net loss of $7.43 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.